{"id":5231,"date":"2012-01-09T09:00:00","date_gmt":"2012-01-09T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/"},"modified":"2024-09-23T11:22:47","modified_gmt":"2024-09-23T11:22:47","slug":"mesochymale-stamcellen-triggeren-geen-afweer","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/","title":{"rendered":"Mesochymale stamcellen triggeren geen afweer"},"content":{"rendered":"Een jaar geleden startte Osiris Therapeutics met Breakthrough T1D een fase 2 klinische trial met Prochymal, een intraveneus toegediend middel dat mesochymale stamcellen (MSC\u2019s) bevat. De stamcellen waren afkomsitg van niet verwante donoren en er werd geen immunosuppressie toegepast bij de ontvangers. Desondanks werd er geen reactie van het afweer systeem geconstateerd. Hoewel de progressie van T1D niet aanwijsbaar werd gereduceerd door Prochymal, leek er wel een trend te zijn dat het aantal hypoglycemische gebeurtenissen afnam. Het onderzoek loopt nog een jaar door.\n\n<a href=\"http:\/\/asweetlife.org\/a-sweet-life-staff\/in-the-news\/type-1-in-the-news\/osiris-provides-update-on-stem-cell-trial-for-type-1-diabetes\/23435\/\">Lees verder <\/a>(Engelstalig)","protected":false,"raw":""},"excerpt":{"rendered":"<p>Een jaar geleden startte Osiris Therapeutics met Breakthrough T1D een fase 2 klinische trial met Prochymal, een intraveneus toegediend middel dat mesochymale stamcellen (MSC\u2019s) bevat. De stamcellen waren afkomsitg van niet verwante donoren en er werd geen immunosuppressie toegepast bij de ontvangers. Desondanks werd er geen reactie van het afweer systeem geconstateerd. Hoewel de progressie [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5231","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Een jaar geleden startte Osiris Therapeutics met Breakthrough T1D een fase 2 klinische trial met Prochymal, een intraveneus toegediend middel dat mesochymale stamcellen (MSC\u2019s) bevat. De stamcellen waren afkomsitg van niet verwante donoren en er werd geen immunosuppressie toegepast bij de ontvangers. Desondanks werd er geen reactie van het afweer systeem geconstateerd. Hoewel de progressie [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2012-01-09T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:47+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Mesochymale stamcellen triggeren geen afweer\",\"datePublished\":\"2012-01-09T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\"},\"wordCount\":93,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\",\"name\":\"Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2012-01-09T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mesochymale stamcellen triggeren geen afweer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/","og_locale":"nl_NL","og_type":"article","og_title":"Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D","og_description":"Een jaar geleden startte Osiris Therapeutics met Breakthrough T1D een fase 2 klinische trial met Prochymal, een intraveneus toegediend middel dat mesochymale stamcellen (MSC\u2019s) bevat. De stamcellen waren afkomsitg van niet verwante donoren en er werd geen immunosuppressie toegepast bij de ontvangers. Desondanks werd er geen reactie van het afweer systeem geconstateerd. Hoewel de progressie [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/","og_site_name":"Breakthrough T1D","article_published_time":"2012-01-09T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:47+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Mesochymale stamcellen triggeren geen afweer","datePublished":"2012-01-09T09:00:00+00:00","dateModified":"2024-09-23T11:22:47+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/"},"wordCount":93,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/","name":"Mesochymale stamcellen triggeren geen afweer - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2012-01-09T09:00:00+00:00","dateModified":"2024-09-23T11:22:47+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/mesochymale-stamcellen-triggeren-geen-afweer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Mesochymale stamcellen triggeren geen afweer"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5231"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5231\/revisions"}],"predecessor-version":[{"id":7344,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5231\/revisions\/7344"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}